Format

Send to

Choose Destination
EBioMedicine. 2015 Feb 26;2(4):351-5. doi: 10.1016/j.ebiom.2015.02.015. eCollection 2015 Apr.

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.

Author information

1
Department of Dermatology, Columbia University, New York, NY, USA.
2
Department of Pathology, Columbia University, New York, NY, USA.
3
Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
4
Department of Pediatrics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
5
Translational Autoinflammatory Disease Section, NIAMS, NIH, Bethesda, MD, USA.
6
Department of Dermatology, Columbia University, New York, NY, USA ; Department of Genetics & Development, Columbia University, New York, NY, USA.
7
Department of Dermatology, Columbia University, New York, NY, USA ; Department of Pathology, Columbia University, New York, NY, USA ; Department of Medicine, Columbia University, New York, NY, USA.

Abstract

BACKGROUND:

Alopecia areata (AA) is an autoimmune disease resulting in hair loss with devastating psychosocial consequences. Despite its high prevalence, there are no FDA-approved treatments for AA. Prior studies have identified a prominent interferon signature in AA, which signals through JAK molecules.

METHODS:

A patient with AA was enrolled in a clinical trial to examine the efficacy of baricitinib, a JAK1/2 inhibitor, to treat concomitant CANDLE syndrome. In vivo, preclinical studies were conducted using the C3H/HeJ AA mouse model to assess the mechanism of clinical improvement by baricitinib.

FINDINGS:

The patient exhibited a striking improvement of his AA on baricitinib over several months. In vivo studies using the C3H/HeJ mouse model demonstrated a strong correlation between resolution of the interferon signature and clinical improvement during baricitinib treatment.

INTERPRETATION:

Baricitinib may be an effective treatment for AA and warrants further investigation in clinical trials.

KEYWORDS:

Alopecia areata; Autoimmune disease; Autoinflammatory; Baricitinib; CANDLE syndrome; Gene expression profiling; Interferon gamma; JAK inhibitor

PMID:
26137574
PMCID:
PMC4486197
DOI:
10.1016/j.ebiom.2015.02.015
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center